Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination ...
U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
FOSTER CITY, Calif.
Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap
Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap
Boehringer to get animal-health unit, pay 4.
After 190 Tries, Are We Any Closer to a Cure for Alzheimer’s?
After 190 Tries, Are We Any Closer to a Cure for Alzheimer’s?
Eli Lilly has spent almost three decades working on drugs for Alzheimer’s disease with not much to show for it yet.
GW Pharmaceuticals plc announces positive results of the Phase 3 clinical trial of its investigational medicine Epidiolex® for the treatment of Lennox-Gastaut syndrome
GW Pharmaceuticals plc announces positive results of the Phase 3 clinical trial of its investigational medicine Epidiolex® for the treatment of Lennox-Gastaut syndrome
London, UK; 27 June 2016.
Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban
Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban
TOKYO, Japan (June 27, 2016) – Daiichi Sankyo Co.
Drinks, drugs and cars: Trade hit by EU vote
Drinks, drugs and cars: Trade hit by EU vote
LONDON.
Teva seals deal to market copy of AstraZeneca diabetes drug
Teva seals deal to market copy of AstraZeneca diabetes drug
Dive Brief.
Pfizer plans to close Colorado production facility
Pfizer plans to close Colorado production facility
Dive Brief.
Brexit vote creates new uncertainty for UK, EU pharma industry
Brexit vote creates new uncertainty for UK, EU pharma industry
Dive Brief.
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
FOSTER CITY, Calif.
New life form discovered in saliva is linked to human disease
New life form discovered in saliva is linked to human disease
Parasitic bacteria that are entirely dependent on the other bacteria they infect have been discovered for the first time, in human spit.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand